- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05320887
Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM)
The Impact of Cigarette Nicotine Content, E-Cigarette Nicotine Content and E-Cigarette Flavoring on Smoking Behavior in an Electronic Tobacco Marketplace
Study Overview
Status
Conditions
Detailed Description
The Family Smoking Prevention and Tobacco Control Act (FSPTCA) passed in 2009 provides the FDA with the authority to regulate tobacco products. One provision in this legislative act empowers the FDA to set limits on constituents in tobacco products, including nicotine. Such a measure has the potential to reduce the chance of individuals experimenting with smoking from becoming dependent and enable current smokers to quit when they are motivated to do so. Although the proposal to reduce nicotine in cigarettes has been met with skepticism by some because of concerns over compensatory smoking behavior and the potential emergence of a black market, this policy measure was considered to be technically feasible by the American Medical Association and the British Medical, by tobacco control researchers, policymakers and governmental officials who were convened in a meeting on nicotine regulation8, and by the World Health Organization Study Group on Tobacco Product Regulation. Most importantly, in July 2017, FDA Commissioner Gottlieb announced he was "directing our Center for Tobacco Products to develop a comprehensive nicotine regulatory plan premised on the need to confront and alter cigarette addiction." This announcement was followed on March 16, 2018 by the release of the Advance Notice of Proposed Rulemaking entitled "Tobacco Product Standard for Nicotine Level of Combusted Cigarettes" (ID: FDA-2017-N-6189-0001) "to obtain information for consideration in developing a tobacco product standard to set the maximum nicotine level for cigarettes."
This study proposes to conduct a within-subjects, multi-session virtual lab study and validation field assessment to determine how the availability of flavored e-liquids affects product purchasing among cigarette smokers. Adult daily cigarette smokers (N=64) will be recruited for this study. After initial eligibility is assessed, participants will complete six virtual sessions (1 baseline, 4 experimental, and 1 follow-up) and one field assessment to evaluate their tobacco use.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Darcy L Laverdiere, BA
- Phone Number: 336-716-6182
- Email: alaverdi@wakehealth.edu
Study Contact Backup
- Name: Eric C Donny, PhD
- Phone Number: 336-713-1520
- Email: edonny@wakehealth.edu
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 21+ years of age
- Self-report smoking at least 5 cigarettes per day for the past year
- Breathe carbon monoxide (CO) level > 8 ppm or positive urine NicCheck
- Willingness to use other tobacco products during the study
- Speak, comprehend, and read English sufficiently to complete study procedures
- Have home access to a computer, smart phone, or tablet with a web camera and internet access
- Tried a vaping device at least once in their lifetime
Exclusion Criteria:
- Currently seeking treatment to quit smoking
- Self-reported serious medical or psychiatric condition(s) including cardiovascular and chronic respiratory diseases
- Body temperature > 100.4 F
- Cold, flu or COVID-19 symptoms including fever, cough, and runny nose in the past 30 days
- Currently pregnant, breastfeeding or intending to become pregnant for the duration of the study or unwilling to agree to use adequate protection to avoid pregnancy
- CO reading > 80 ppm
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Normal Nicotine Content Vape with all flavor e-liquids
|
Participants are randomly assigned to the order of each marketplace Group
|
Experimental: Normal nicotine content vape with tobacco e-liquids
|
Participants are randomly assigned to the order of each marketplace Group
|
Experimental: Low nicotine content vape with all flavor e-liquids
|
Participants are randomly assigned to the order of each marketplace Group
|
Experimental: Low nicotine content vape with tobacco e-liquids
|
Participants are randomly assigned to the order of each marketplace Group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of cigarettes purchased
Time Frame: 1 year
|
Number of cigarettes purchased (analyzed as raw data and using derived behavioral economic measures)
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amount of E-liquid purchased
Time Frame: 1 year
|
E-liquid purchased (analyzed as raw data and using derived behavioral economic measures)
|
1 year
|
Proportion of Participants completing Flavor and Nicotine Content Discrete Choice Projections
Time Frame: 1 year
|
The proportion of participants projected to choose a cigarette over an e-cigarette under different potential regulatory scenarios, as determined by logistic regression
|
1 year
|
Perceived Health Risk Scale Scores
Time Frame: 1 year
|
Perceived Health Risk Scale - The response options rely on a 5-point Likert-like scale: 0=no risk; 1=low risk; 2=moderate risk; 3=high risk; 4=very high risk
|
1 year
|
Product Evaluation Scale Scores
Time Frame: 1 year
|
Product Evaluation Scale - which measures responses to cigarettes (e.g., reward, satisfaction) - The response options rely on a 7-point Likert-like scale: 1=not at all; 2= very little; 3= a little; 4= moderately; 5= a lot; 6= quite a lot; 7= extremely
|
1 year
|
Minnesota Nicotine Withdrawal Scale Scores
Time Frame: 1 year
|
Minnesota Nicotine Withdrawal Scale - a measure of nicotine withdrawal symptoms.
The response options rely on a 5-point Likert-like scale; 0=None; 1= Slight; 2=Mild; 3=Moderate; 4=Severe
|
1 year
|
Questionnaire on Smoking Urges Score
Time Frame: 1 year
|
Questionnaire on Smoking Urges - measures the urge to smoke.
The response options rely on a 7-point Likert-like scale: 1=Strongly Disagree; 2; 3; 4; 5; 6; 7= Strongly Agree
|
1 year
|
Tobacco Product Interest Scores
Time Frame: 1 year
|
Tobacco Product Interest of different products; Slider scale ranging from 0=No Interest to 100=Very Interested
|
1 year
|
Tobacco Policy Questionnaire Scores
Time Frame: 1 year
|
Tobacco Policy Questionnaire scored from Support, Oppose, and Don't know for personal opinions on relevant Tobacco Policies
|
1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Product use themes emerging from the qualitative interviews
Time Frame: 1 year
|
Participants are asked about their opinions and experiences using tobacco products other than their usual brand during the field assessment.
|
1 year
|
Tobacco Product use during Field Assessment
Time Frame: 1 year
|
Participants are asked what products they had used and quantity every day during the field assessment.
|
1 year
|
Biomarkers of exposure during Field Assessment - Carbon Monoxide
Time Frame: 1 year
|
Product use and biomarkers of exposure during the field assessment will be analyzed using linear regression or other appropriate regression models.
The model for primary analysis of these data will include main effects for each of the two factors (for the ETM condition carried into the field assessment), and the corresponding baseline measure to improve precision.
Carbon Monoxide (CO) is collected in ppm.
|
1 year
|
Biomarkers of exposure during Field Assessment - Cotinine
Time Frame: 1 year
|
Product use and biomarkers of exposure during the field assessment will be analyzed using linear regression or other appropriate regression models.
The model for primary analysis of these data will include main effects for each of the two factors (for the ETM condition carried into the field assessment), and the corresponding baseline measure to improve precision.
Cotinine is collected in ng/ml.
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eric M Donny, PhD, Wake Forest University Health Sciences
Publications and helpful links
General Publications
- Jarvis MJ, Bates C. Eliminating nicotine in cigarettes. Tob Control. 1999 Spring;8(1):106-7; author reply 107-9. No abstract available.
- Kozlowski LT. Prospects for a nicotine-reduction strategy in the cigarette endgame: Alternative tobacco harm reduction scenarios. Int J Drug Policy. 2015 Jun;26(6):543-7. doi: 10.1016/j.drugpo.2015.02.001. Epub 2015 Feb 23.
- Kozlowski LT. Cigarette prohibition and the need for more prior testing of the WHO TobReg's global nicotine-reduction strategy. Tob Control. 2017 Mar;26(e1):e31-e34. doi: 10.1136/tobaccocontrol-2016-052995. Epub 2016 Jun 29. No abstract available.
- Kozlowski LT. Let actual markets help assess the worth of optional very-low-nicotine cigarettes before deciding on mandatory regulations. Addiction. 2017 Jan;112(1):3-5. doi: 10.1111/add.13515. Epub 2016 Aug 23. No abstract available.
- Shatenstein S. Eliminating nicotine in cigarettes. Tob Control. 1999 Spring;8(1):106; author reply 107-9. No abstract available.
- Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control. 1998 Autumn;7(3):281-93. doi: 10.1136/tc.7.3.281.
- Hatsukami DK, Perkins KA, Lesage MG, Ashley DL, Henningfield JE, Benowitz NL, Backinger CL, Zeller M. Nicotine reduction revisited: science and future directions. Tob Control. 2010 Oct;19(5):e1-10. doi: 10.1136/tc.2009.035584.
- World Health Organization. WHO STUDY GROUP ON TOBACCO PRODUCT REGULATION. Report on the Scientific Basis of Tobacco Product Regulations: Fifth Report of a WHO Study Group. World Health Organ Tech Rep Ser. 2015;(989):1-234, back cover.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00080010
- 5U54DA031659-09 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tobacco Use
-
University of VirginiaVirginia Foundation for Healthy YouthRecruitingTobacco Use | Electronic Cigarette Use | Tobacco Use CessationUnited States
-
Vanderbilt University Medical CenterCompletedTobacco Use | Tobacco Use Cessation
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Electronic Cigarette Use | Cigarette Use, ElectronicUnited States
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Nicotine Dependence | Tobacco Dependence | Smoking, Tobacco | Nicotine Use Disorder | Nicotine Dependence, Cigarettes | Smoking, Cigarette | Nicotine Dependence Tobacco Product | Tobacco; Use, Rehabilitation | Smoking (Tobacco) Addiction and other conditionsUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
British American Tobacco (Investments) LimitedCompletedTobacco Use | Tobacco SmokingUnited States
-
Philip Morris Products S.A.CompletedSmoking | Tobacco Use | Tobacco SmokingUnited Kingdom
Clinical Trials on Normal Nicotine Content Vape with all flavor e-liquids
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Yale UniversityNational Institute on Drug Abuse (NIDA)RecruitingSmoking | Nicotine Dependence | Smoking BehaviorsUnited States
-
Milton S. Hershey Medical CenterNational Institute on Drug Abuse (NIDA)Recruiting
-
Insel Gruppe AG, University Hospital BernSwiss National Science FoundationRecruiting
-
Florida International UniversityCompletedElectronic Cigarette UseUnited States
-
University of MinnesotaUniversity of Pennsylvania; Brown University; Duke University; University of California... and other collaboratorsCompletedTobacco Smoking | Nicotine DependenceUnited States
-
Milton S. Hershey Medical CenterNational Institutes of Health (NIH)RecruitingTobacco DependenceUnited States
-
Duke UniversityNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)CompletedSmoking | Nicotine Dependence | Smoking, Cigarette | E-Cig UseUnited States
-
Brown UniversityNational Institute on Drug Abuse (NIDA); University of Vermont; Food and Drug...Active, not recruitingTobacco Use DisorderUnited States
-
Duke UniversityNational Institute on Drug Abuse (NIDA)CompletedNicotine DependenceUnited States